InvestorsHub Logo
Followers 0
Posts 16
Boards Moderated 0
Alias Born 04/12/2023

Re: Slojab post# 58330

Wednesday, 04/19/2023 12:34:21 AM

Wednesday, April 19, 2023 12:34:21 AM

Post# of 58491
About a month before the big run up to .0189 stock high in 2021, Armenta and Lovatt sold all their common shares and created Supplement Group Europe, which would control everything in GTEH, with 1 preferred share.

The way they would get compensated was through an agreement between their two owned entity, GTEH & Supplement Group Europe, for a tune of $50k/month.
GTEH/SGEurope Agreement

They also had an agreement with TQLB and Supplement Group Europe. Yeah, they had multiple owned public company under their private entity. How convenient, especially when you can sell one subsidary (American Metabolix) from one public company to your other, for cash. *Shareholder's cash* Then flip it for more cash, at the end of its cycle and pocket that.
TQLB/SGEurope Agreement

So how else do you create value for yourself, as an owner, if you have 0 common shares? Sell diluted shares while selling out assets. A few months after Supplement Group Europe came about, the A/S was raised to 40Billion. Remember, in 2019/2020, they made shareholders believe that they were not going to dilute any further. In fact, they were going to heavily reduce it. Anti-Dilution Initiative

There's also Donnell Suarez, who is an attorney. Pretty much does background work. However, Lovatt's Green Light Development overlaps it but it still receives $8k/month since 2017, when GTEH was still PKGM. Essentially, Lovatt pays himself through different private channels. Suarez received 2,753,000,000 shares. Was that a reasonable fee for an attorney? That represented 9% of the entire float. What did Suarez really do for GTEH for that amount?

Had the reverse split went through, Lovatt was proposing a 500:1 Reverse Split. That would have left the Outstanding share at 61 Million but the Authorized share at 12 Billion. Think about that. Lovatt was saying the A/S would be "in line" with the O/S. laughs

Kyle Brammer (Sales Director) left Dec. 2022
Josh Pittman, (COO) left Jan. 2023
RJ Runowski (VP) left Summer 2022


Yet, Lovatt continued to try to pump this albeit lesser and lesser as he finally announced the R/S was cancelled in February 2023. But this is not the first time the 500:1 R/S was cancelled. The same thing happened in 2020:
2020 500:1 R/S Cancellation

Except, the first time around, it took two months to get announced. The timing of the second 500:1 R/S is suspect. A few weeks before Lovatt's annoucement of the cancellation, Armenta brings back JACS Nutrition, from (Deliquent) to (Good Standing.)
JACS Nutrition Filing
Colorado State: JACS Nutrition

That's 13 years ago. Why now? They already gave up TQLB & PDPG, Sinfit & American Metabolix, all at the cost of shareholders. Is JACS Nutrition the next thing? Lovatt also has some ownership in ARMC, but that came as part of a package when he took over TQLB, formerly known as Commodore International. But who really knows, with the amount of tickers he went through in the past.

Then there's the whole rule 144 thing.
Rule 144 /Basile Law Firm
This has a connection to the current lawsuit (East Capital Investments Corp. v. GenTech Holdings, Inc.). You can see, Basile Law Firm pulled their representation out. ECIC v. GTEH

The Link above, about rule 144 from SPCC (Small Public Company Coalition), mentions both Basile Law Firm and Lovatt (GTEH).

The letter in question about Lovatt and Rule 144 is linked below:
SEC/Rule144 Lovatt

You can see it was written and dated on November 30, 2021. However, many unrestricted/free-trading occured soon after, dropping the share price to where it is now.

It's not really about the products, how good or bad it is. It's the toxic shares being sold while funneling money out to private owned companys, all owned by themselves. Possibly leaving Supplement Group USA to take all the liabilities?

And Fizzique, even if it was great, wasn't going to last long anyway. Its patent will expire in 2025. And Next Proteins Inc. (David Jenkins) owns it, not GTEH.

Hopefully that gave you an even better insight.